Summary

Launched
2022
Estimated duration
3 Years
Estimated total value
$15,859,166.00
Partners
Allen, Chesson & Grimes, Amazon Web Services, Beyond Advisers, Brownstein Group, Buchanan Ingersoll & Rooney PC, Castleman Disease Collaborative Network, Center for Cytokine Storm Treatment and Laboratory, CURE Drug Repurposing Collaboratory, Dr. Evidence, Eversana, Form Bio, Hugh Kaul Precision Management, University of Alabama, Birmingham, JM Collaborative, Manifold AI, Monarch Initiative, Pharma Science, Playground Agency, Spence

Unlocking the hidden potential of existing drugs to save lives

Summary

In 2022, Every Cure committed to launching efforts to unlock all diseases that all existing drugs can treat by developing a comprehensive, open-source database of drug repurposing opportunities, and launching clinical trials of the most promising treatments.

Approach

Every Cure is dedicated to unlocking all diseases that all existing drugs can treat by developing a comprehensive, open-source database of drug repurposing opportunities, and launching clinical trials of the most promising treatments. Specifically, Every Cure will obtain, integrate, and analyze multiple data sources (e.g. PubMed, public data repositories, clinicaltrials.gov, medical record data, pathway and drug databases) , utilize natural language processing, and apply a machine learning algorithm modeled after its COVID-19 algorithm to identify the most promising drug repurposing opportunities. Every Cure will integrate insights from disease experts and pharmaceutical companies to further refine its assessment of the most promising repurposing opportunities and partner with disease research organizations to perform clinical trials of these opportunities. This approach has previously identified drug repurposing opportunities for Castleman disease, COVID-19, and angiosarcoma, and an initial pilot uncovered 106 promising drug repurposing opportunities in a first-set of 147 diseases. Now, Every Cure is scaling this work to all known diseases and drugs.

This project overcomes systemic challenges that have impeded the identification of all potential uses for all drugs by aggregating data and aligning stakeholders and financial incentives. The non-profit organizational structure will ensure that generic drugs with no commercial incentive for repurposing will be pursued by Every Cure in promising new indications. Their team will contribute expertise in drug discovery and repurposing, patient-driven research, informatic analyses, and clinical trial execution. Every Cure will establish collaborative partnerships with leading philanthropic organizations, medical informatics firms, tech companies, and biopharmaceutical companies, among others to obtain funding, data, data science tools, and actionable insights.

Action Plan

Every Cure will establish an open-source database of all potential drug repurposing opportunities and apply a machine learning algorithm to systematically evaluate and identify the most promising opportunities to move forward into clinical trials. Our action plan includes the following steps:

December 2022:

Complete initial version of the open-source database

March 2023:

Establish a preliminary list of the 100 most promising drug repurposing opportunities across all diseases for further investigation

June 2023:

Complete build of a comprehensive version of the database and make all promising drug repurposing opportunities available through an open-source platform

September 2023:

Select the top 15 repurposing opportunities for further clinical studies by Every Cure and/or in partnership with external organizations

December 2023:

Finalize partnerships to perform further clinical studies for the most promising drug repurposing opportunity within 6 months

March 2024:

Select sites for initial clinical trial of the most promising drug repurposing opportunity

June 2024:

Launch clinical trial of the most promising drug repurposing opportunity

September 2024:

Refine and update the list of the top 15 repurposing opportunities for further clinical studies

December 2024:

Secure funding and finalize partnerships to perform further clinical studies for the next 7 most promising drug repurposing opportunities ($1-5M per drug-disease pair) March 2025:

Launch clinical trials of the next 7 most promising drug repurposing opportunities (pending identifying funding beyond this CTA) June 2025:

Establish a refined list of the top 100 remaining repurposing opportunities

September 2025:

Launch clinical trials of the next 7 most promising drug repurposing opportunities (pending identifying funding beyond this CTA)

Background

Patients around the world die every day from diseases that could have been cured by a drug sitting on the shelf at their local pharmacy. Unfortunately, no one knows to try these drugs because no systematic efforts have been made to unlock the full potential of their use across diseases. Though many diseases share common mechanisms and can benefit from the same drugs, the ~3,000 FDA-approved treatments are only approved for ~3,000 human diseases and another ~9,000 diseases affecting millions of people do not have any approved treatments. The current model requires $1-2B and 10-15 years to develop a single new FDA-approved drug. Repurposing safe, widely available drugs for new indications is faster and less expensive, with the greatest return on investment for saving lives.

Repurposing drugs has proven effective for Castleman disease (CD) and other conditions. Every Cure co-founder Dr. David Fajgenbaum nearly died five times from CD before discovering that the inexpensive transplant drug sirolimus was also effective for CD. This discovery has saved countless patients’ lives, including Dr. Fajgenbaum’s and inspired the creation of Every Cure. Dr. Fajgenbaum’s team has identified 9 other CD treatments as well as treatments for cancer and COVID-19, including guiding the selection of drugs for the groundbreaking ACTIV-6 clinical trial. Incredibly, dexamethasone and tocilizumab, which were rapidly repurposed as treatments for COVID-19, have likely saved the most lives during this pandemic.

Unfortunately, insufficient incentives, siloed data, misaligned stakeholders, and other market failures have impeded the identification of all potential uses for all drugs, especially low-cost, generic drugs. The incomplete utilization of existing drugs and focus on new, expensive drugs has a disproportionately negative impact on individuals in areas with reduced access to medicines.

Society needs a systematic effort to identify the most promising drug repurposing opportunities and bring them to patients, which would save precious lives and enormous costs.

Progress Update

Every Cure has made strong progress since its launch in 2022 toward its mission of ensuring every drug is unlocked to treat every disease that it possibly can. To accomplish that, Every Cure is building the world’s most advanced database dedicated to drug repurposing. It then uses an AI engine to predict which of the current ~3,000 FDA approved drugs can treat the ~9,000 human diseases that patients suffer from that have no approved treatment. Since launch, Every Cure has developed strong relationships with all key drug repurposing stakeholders such as NCATS and Cures Within Reach, launched 12 collaborations with foundations and rare disease groups such as Chan Zuckerberg Initiative and its Rare as One cohorts, and secured millions of dollars in data contributions and strategic support from major health data organizations such as Elsevier, Eversana and Medidata. In collaboration with its partners at Penn State and RENCI, Every Cure performed the first “all drug vs all disease” machine learning query using human biology knowledge graphs. This query produced a predictive score for all 36M possible combinations of drugs and disease. The top results instantly replicated work that had required two years in the lab for Every Cure to develop, identifying a novel repurposed treatment that saved a patient’s life in February 2023.

Every Cure has received verbal commitments and in-kind services representing just under half of its $16mm goal for 2023. Once Every Cure secures those commitments and its remaining funding, it will be able to complete its AI engine to identify dozens more lifesaving treatments that are hiding in plain sight on pharmacy shelves. It will also take the 36 million drug-disease pair scores and publish them in a publicly accessible “heatmap” that will accelerate research globally and give hope to patients who were told, “we’ve tried everything.”

Partnership Opportunities

Every Cure is seeking $15.8 million USD to initiate buildout of the open-source database by the end of 2022 and launch the first clinical trial of the most promising drug repurposing opportunity within 18 months. Separate from this Commitment to Action, Every Cure is seeking an additional $45M to perform clinical trials of the next 15 most promising drug repurposing opportunities ($1-5M per drug-disease) . Every Cure is also seeking access to proprietary medical data and data analytic tools (e.g. medical record data, network data on published studies, and drug/disease database data) , partnerships with disease research organizations and biopharmaceutical companies to evaluate potential repurposing opportunities and/or collaborate on clinical trials, data resources such as cloud computing, and legal services, marketing fees, and office space to lower costs so that funding can be focused on treatment discovery and saving lives

Every Cure is offering the below resources and/or services as part of partnering. Every Cure is offering disease research organizations the opportunity to utilize insights and potentially receive financial resources for collaborative clinical trials. Partners providing access to proprietary medical data and analytic tools will be highlighted publicly for their contributions and given preferential access to insights. Biopharmaceutical companies contributing medical data and insights will be profiled publicly and engaged to generate meaningful insights. Anchor fundraising partners will be highlighted in all materials and media engagements.

NOTE: This Clinton Global Initiative (CGI) Commitment to Action is made, implemented, and tracked by the partners listed. CGI is a program dedicated forging new partnerships, providing technical support, and elevating compelling models with potential to scale. CGI does not directly fund or implement these projects.